Gossamer Bio (NASDAQ:GOSS) Receives Outperform Rating from Wedbush

Wedbush reissued their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research report report published on Friday morning,Benzinga reports. Wedbush currently has a $4.00 price target on the stock.

A number of other research firms also recently commented on GOSS. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a research note on Tuesday, March 18th. The Goldman Sachs Group decreased their price target on Gossamer Bio from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, April 17th.

Gossamer Bio Stock Down 1.0%

NASDAQ:GOSS opened at $1.04 on Friday. The company has a market capitalization of $236.31 million, a price-to-earnings ratio of -3.25 and a beta of 1.82. Gossamer Bio has a one year low of $0.50 and a one year high of $1.55. The stock has a 50-day simple moving average of $1.04 and a 200 day simple moving average of $0.99. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $9.89 million during the quarter, compared to analyst estimates of $3.95 million. Sell-side analysts predict that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Gossamer Bio

Large investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its holdings in Gossamer Bio by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company’s stock worth $1,123,000 after acquiring an additional 13,902 shares during the last quarter. Silverarc Capital Management LLC lifted its holdings in Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock worth $5,583,000 after acquiring an additional 526,495 shares during the last quarter. Allostery Investments LP bought a new position in Gossamer Bio in the fourth quarter worth about $555,000. Alyeska Investment Group L.P. lifted its holdings in Gossamer Bio by 52.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock worth $7,968,000 after acquiring an additional 3,041,058 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Gossamer Bio by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company’s stock worth $2,037,000 after acquiring an additional 38,084 shares during the last quarter. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.